<?xml version="1.0" encoding="UTF-8"?>
<feed xmlns="http://www.w3.org/2005/Atom">
  <id>https://recalls.watch/feed/substance-atropine.xml</id>
  <title>Recalls Watch: Atropine</title>
  <link rel="self" href="https://recalls.watch/feed/substance-atropine.xml"/>
  <link href="https://recalls.watch/alerts/"/>
  <updated>2026-08-26T00:00:00Z</updated>
  <entry>
    <id>https://recalls.watch/recall/fda/99503/</id>
    <title>American Regent, Inc.: Nitroglycerin injection and 11 more</title>
    <link href="https://recalls.watch/recall/fda/99503/"/>
    <updated>2026-08-26T12:00:00Z</updated>
    <category term="drugs"/>
    <summary>FDA: Presence of Particulate Matter: Product contaminated with particulate matter identified as hair, glass and/or paraformaldehyde Presence of Particulate Matter: Product contaminated with particulate matter identified as glass and/or paraformaldehyde</summary>
  </entry>
  <entry>
    <id>https://recalls.watch/recall/fda/95997/</id>
    <title>SOMERSET THERAPEUTICS LLC: Atropine Sulfate Ophthalmic Solution</title>
    <link href="https://recalls.watch/recall/fda/95997/"/>
    <updated>2025-01-08T12:00:00Z</updated>
    <category term="drugs"/>
    <summary>FDA: Failed Impurities/Degradation Specifications</summary>
  </entry>
  <entry>
    <id>https://recalls.watch/recall/fda/93681/</id>
    <title>Pfizer Inc.: 4.2% Sodium Bicarbonate Injection and 2 more</title>
    <link href="https://www.accessdata.fda.gov/scripts/ires/index.cfm?Event=93681"/>
    <updated>2024-01-24T12:00:00Z</updated>
    <category term="drugs"/>
    <summary>FDA: Presence of Particulate Matter; identified as glass</summary>
  </entry>
  <entry>
    <id>https://recalls.watch/recall/fda/91788/</id>
    <title>Akorn, Inc.: Atropine Sulfate Ophthalmic Solution and 85 more</title>
    <link href="https://www.accessdata.fda.gov/scripts/ires/index.cfm?Event=91788"/>
    <updated>2023-06-07T12:00:00Z</updated>
    <category term="drugs"/>
    <summary>FDA: CGMP Deviations: Firm went out of business and could no longer continue stability studies.</summary>
  </entry>
  <entry>
    <id>https://recalls.watch/recall/fda/91580/</id>
    <title>Akorn, Inc.: Atropine Sulfate Ophthalmic Solution</title>
    <link href="https://www.accessdata.fda.gov/scripts/ires/index.cfm?Event=91580"/>
    <updated>2023-02-15T12:00:00Z</updated>
    <category term="drugs"/>
    <summary>FDA: Failed Stability Specifications: Out of specification test results for viscosity was identified at the 12M stability timepoint.</summary>
  </entry>
  <entry>
    <id>https://recalls.watch/recall/fda/90982/</id>
    <title>Pharmacy Plus, Inc. dba Vital Care Compounder: ACETYLCYSTEINE OPTH 10% Solution and 31 more</title>
    <link href="https://www.accessdata.fda.gov/scripts/ires/index.cfm?Event=90982"/>
    <updated>2022-11-09T12:00:00Z</updated>
    <category term="drugs"/>
    <summary>FDA: Lack of Assurance of Sterility: FDA inspection found the recalled products were produced in a manner than cannot guarantee the sterility of the products purported to be sterile.</summary>
  </entry>
  <entry>
    <id>https://recalls.watch/recall/fda/65360/</id>
    <title>Lowlite Investments, Inc. D/B/A Olympia Pharmacy: Acetyl-D-Glucosamine w/Chondroitin 200 mg/ml and 104 more</title>
    <link href="https://www.accessdata.fda.gov/scripts/ires/index.cfm?Event=65360"/>
    <updated>2013-07-17T12:00:00Z</updated>
    <category term="drugs"/>
    <summary>FDA: Lack of Assurance of Sterility: FDA inspection findings resulted in concerns regarding quality control processes</summary>
  </entry>
</feed>
